<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676468</url>
  </required_header>
  <id_info>
    <org_study_id>07-11765</org_study_id>
    <nct_id>NCT00676468</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma</brief_title>
  <official_title>Comparative Effects of Fish Oil Supplementation and a Leukotriene Receptor Antagonist on EIB and Airway Inflammation in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combining fish oil supplementation and Montelukast [a commonly used cyst LT1 receptor
      antagonist to treat exercise-induced bronchoconstriction (EIB)] will provide a greater
      antiinflammatory effect against developing EIB that either agent alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to extend previous published findings that fish oil supplementation
      represents a beneficial treatment on exercise-induced bronchoconstriction (EIB). An important
      question is how dietary fish oil supplementation fits in with the available armamentarium
      [e.g., leukotriene (LT) modifiers] to decrease the expression of LTs, and whether fish oil
      supplementation may be additive, or used in its own right to block the EIB response. For
      example, it is possible that a combination of fish oil supplementation and a cyst LT1
      receptor antagonist (LTRA) may provide a greater antiinflammatory effect against developing
      EIB that either agent alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled breathe condensate markers to measure airway inflammation</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Montelukast + Fish Oil Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Fish Oil + Montelukast Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Montelukast + Active Fish Oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Montelukast + Fish Oil Placebo</intervention_name>
    <description>Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Singulair (montelukast). Placebo (no brand name).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Fish Oil + Montelukast Placebo</intervention_name>
    <description>10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pro-Omega Fish Oil. Montelukast placebo (no brand name).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Montelukast + Active Fish Oil</intervention_name>
    <description>1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Singulair (Montelukast) and Pro-Omega (Fish Oil).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrate a fall in post-exercise FEV1 of &gt; 10% after dry air exercise challenge for
             the diagnosis of EIB and

          -  &gt; 12% increase in FEV1 from the baseline value after the administration of a
             Î²2-agonist. However, if the bronchodilator response is &lt; 12% increase in FEV1 from the
             baseline value then asthmatic subjects with EIB must further demonstrate

          -  A &lt; 16.0 mg.ml-1 concentration of methacholine causing a 20% decrease in FEV1 (PC20)

        Exclusion Criteria:

          -  Subjects will be excluded if they are pregnant

          -  Have a history of hyperlipidemia, hypertension, diabetes, bleeding disorders, delayed
             clotting time

          -  Taking aspirin medication and have a resting FEV1 less than 65% predicted.

          -  A complete blood count and urinary pregnancy tests will be conducted at the beginning
             of the study and subjects with a hematocrit &lt; 35 will be excluded from participation
             in the study.

          -  In addition, subjects will also be excluded if they have a history of taking n-3 PUFA
             supplements or supplements with antioxidants above the levels recommended for Adequate
             Intake, or regularly consume more than one fish meal per week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy D Mickleborough, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mickleborough TD, Murray RL, Ionescu AA, Lindley MR. Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med. 2003 Nov 15;168(10):1181-9. Epub 2003 Aug 6.</citation>
    <PMID>12904324</PMID>
  </reference>
  <reference>
    <citation>Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest. 2006 Jan;129(1):39-49.</citation>
    <PMID>16424411</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>October 8, 2009</last_update_submitted>
  <last_update_submitted_qc>October 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Timothy D Mickleborough / Associate Professor</name_title>
    <organization>Indiana University</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Airway</keyword>
  <keyword>Fish Oil</keyword>
  <keyword>Singulair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Leukotriene Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

